Peptide ligands

Details Peptide ligands Peptide ligands

2004-06-07

2010-10-26

Bradley, Christina (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S018700, C435S455000

Reexamination Certificate

active

07820624

ABSTRACT:
A peptide consisting of or comprising an amino acid sequence selected froma) PX1X2X3T [SEQ.ID.NO.:1];b) PSX4S [SEQ.ID.NO.:2];c) QX5X6X7Q [SEQ.ID.NO.:3];d) SX8S [SEQ.ID.NO.:4],in which X1, X2and X3, which may be the same or different, each represents an amino acid residue;X4represents an amino acid residue; andX5and X7, which may be the same or different, each represents an amino acid residue, X6represents an amino acid residue having an amide side chain; andX8represent an amino acid having an aliphatic side chain, which peptide binds to dendritic cells and also to other types of cells. The peptide may be used a target non-viral and viral vectors to such cells.

REFERENCES:
patent: 5976787 (1999-11-01), Velicer et al.
patent: 2008/0234183 (2008-09-01), Hallbrink et al.
patent: 198 45 251 (2000-03-01), None
patent: WO 91/18010 (1991-11-01), None
patent: WO 9704105 (1997-02-01), None
patent: WO 98/44121 (1998-10-01), None
patent: WO 98/54347 (1998-12-01), None
patent: WO 0112816 (2001-02-01), None
patent: WO 01/58940 (2001-08-01), None
patent: WO 02/057445 (2002-07-01), None
patent: WO 02/057447 (2002-07-01), None
patent: WO 02/072616 (2002-09-01), None
patent: WO 03/004646 (2003-01-01), None
patent: WO 03/008537 (2003-01-01), None
patent: WO 03/094974 (2003-11-01), None
patent: WO 03/008537 (2003-12-01), None
Office Action, dated Jan. 20, 2010, issued in European patent application No. 04 736 220.7.
Bachman et al., “Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides”,J. Mol. Med., 76(2): 126-132 (1998).
Bandyopadhyay, “Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNA oligonucleotides. Targeted delivery of liposomes and polyethyleneimine to the asialoglycoprotein receptor”,J. Biol. Chem., 274(15): 10163-10172 (1999).
Bettinger et al., “Size reduction of galactosylated PEI/DNA complexes improves lectin-mediated gene transfer into hepaotcytes”,Bioconjugate Chem. 10(4): 558-561 (1999).
Boer et al., “Design and synthesis of potent and selective alpha(4)beta(7) integrin antagonists”,J. Med. Chem., 44(16): 2586-2592 (2001).
Brandao et al., “CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation”,Vaccine, 21(19-20): 2268-2272 (2003).
Boussif et al., “A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine”Proc. Natl. Acad. Sci. USA, 92(16): 7297-7301 (1995).
Castilho et al., “An integrated process for mammalian cell perfusion cultivation and product purification using a dynamic filter”,Biotechnol. Prog., 18(4): 776-781 (2002).
Chowdhury et al., “Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo. Prolonged persistence in cytoplasmic vesicles after partial hepatectomy”,J. Biol.Chem., 268(15): 11265-11271 (1993).
Cole-Strauss et al., “Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide”,Science, 273(5280): 1386-1389 (1996).
Cruz et al., “Process development of a recombinant antibody/interleukin-2 fusion protein expressed in protein-free medium by BHK cells”,J. Biotechnol., 96(2): 169-183 (2002).
Curiel et al., “Adenovirus enhancement of transferring-polylysine-mediated gene delivery”,Proc. Natl. Acad. Sci. USA, 88(19): 8850-8854 (1991).
Durocher et al., “High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells”,Nucleic Acids Res., 30(2): E9 (2002).
Ehsan et al., “Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy”,J. Thorac. Cardiovasc. Surg., 121(4): 714-722 (2001).
Ehsan et al., “Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease”,Circulation, 105(14): 1686-1692 (2002).
Erbacher et al., “Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway”,Gene Therapy, 6(1): 138-145 (1999).
Felgner et al., “Nomenclature for synthetic gene delivery systems”,Hum. Gene Ther., 8(5): 511-512 (1997).
Goncz et al., “Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments”,Hum. Mol. Genet., 7(12): 1913-1919 (1998).
Groth et al., “A phage integrase directs efficient site-specific integration in human cells”,Proc. Natl. Acad. Sci. USA, 97(11): 5995-6000 (2000).
Han et al., “Receptor-mediated gene transfer to cells of hepatic origin by galactosylated albumin-polylysine complexes”,Biol. Pharm. Bull., 22(8): 836-840 (1999).
Ivanenkov et al., “Targeted delivery of multivalent phage display vectors into mammalian cells”,Biochimica et Biophysica Acta, 1448(3): 463-472 (1999).
Knudsen et al., “Application of peptide nucleic acid in cancer therapy”,Anti-cancer Drugs, 8(2): 113-118 (1997).
Kren et al., “In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides”,Nat. Med., 4(3): 285-290 (1998).
Krieg et al., “CpG motifs in bacterial DNA trigger direct B-cell activation”,Nature, 374(6522): 546-549 (1995).
Mann et al., “Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the Prevent single-centre, randomized, controlled trial”,Lancet, 354(9189): 1493-1498 (1999).
Mannion et al., “Sustained reduction of neointima with c-myc antisense oligonucleotides in saphenous vein grafts”,Ann. Thorac. Surg., 66(6): 1948-1952 (1998).
Morishita et al., “A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo”,Proc. Natl. Acad. Sci. USA, 92(13): 5855-5859 (1995).
Nicklin et al., “Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus”,Mol. Ther., 4(6): 534-542 (2001).
Olivares et al., “Phage R4 integrase mediates site-specific integration in human cells”,Gene, 278(1-2): 167-176 (2001).
Pereboev et al., “Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells”,Gene Ther., 9(17): 1189-1193 (2002).
Reddy et al., “Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy”,J. Pharm. Sci., 88(11): 1112-1118 (1999).
Reddy et al., “Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation”,J. Controlled Release, 64(1-3): 27-37 (2000).
Rosenkranz et al., “Receptor-mediated endocytosis and nuclear transport of a transfecting DNA contruct”,Exp. Cell Res., 199(2): 323-329 (1992).
Shi Y., “Mammalian RNAi for the masses”,Trends Genet., 19(1) 9-12 (2003).
Stoll et al., “Phage TP901-1 site-specific integrase functions in human cells”,J. Bacteriol., 184(13): 3657-3663 (2002).
Thyagarajan et al., “Mammalian genomes contain active recombinase recognition sites”,Gene, 244(1-2): 47-54 (2000).
Thyagarajan et al., “Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase”,Mol. Cell. Biol., 21(12): 3926-3934 (2001).
Tillman et al., “Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector”,J. Immunol., 162(11): 6378-6383 (1999).
Wade-Martins et al., “Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells”,Molecular Therapy, 7(5 Pt 1): 604-612 (2003).
Wang et al., “Increasing epitheli

Affiliated with

Also associated with

Rating

Peptide ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4240628